{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.3","upperLimit":"19.4","value":"17.5"},{"groupId":"OG001","lowerLimit":"59.0","upperLimit":"59.0","value":"59.0"},{"groupId":"OG002","lowerLimit":"261","upperLimit":"365","value":"313"},{"groupId":"OG003","lowerLimit":"240","upperLimit":"247","value":"244"},{"groupId":"OG004","lowerLimit":"266","upperLimit":"266","value":"266"},{"groupId":"OG005","lowerLimit":"115","upperLimit":"319","value":"240"},{"groupId":"OG006","lowerLimit":"130","upperLimit":"293","value":"224"},{"groupId":"OG007","lowerLimit":"275","upperLimit":"341","value":"327"},{"groupId":"OG008","lowerLimit":"91.3","upperLimit":"392","value":"247"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"13"}],"units":"Participants"}],"title":"Cycle 1-End of Infusion"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.6","upperLimit":"23.6","value":"23.6"},{"groupId":"OG001","lowerLimit":"62.3","upperLimit":"62.3","value":"62.3"},{"groupId":"OG002","lowerLimit":"302","upperLimit":"302","value":"302"},{"groupId":"OG003","lowerLimit":"448","upperLimit":"448","value":"448"},{"groupId":"OG005","lowerLimit":"233","upperLimit":"380","value":"311"},{"groupId":"OG006","lowerLimit":"253","upperLimit":"253","value":"253"},{"groupId":"OG007","lowerLimit":"356","upperLimit":"490","value":"423"},{"groupId":"OG008","lowerLimit":"328","upperLimit":"466","value":"371"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"4"}],"units":"Participants"}],"title":"Cycle 3-End of infusion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"13"}],"units":"Participants"}],"description":"Median, minimum, and maximum concentration of AMG 655 at specified time points.","dispersionType":"Full Range","groups":[{"description":"AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG000","title":"Part 1 Cohort 1"},{"description":"AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG001","title":"Part 1 Cohort 2"},{"description":"AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG002","title":"Part 1 Cohort 3"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Non-squamous NSCLC","id":"OG003","title":"Part 2 Cohort 1"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Squamous Non -Small Cell Lung Cancer (NSCLC)","id":"OG004","title":"Part 2 Cohort 2"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Colorectal Cancer (CRC)","id":"OG005","title":"Part 2 Cohort 3"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Pancreatic Cancer","id":"OG006","title":"Part 2 Cohort 4"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Ovarian Cancer","id":"OG007","title":"Part 2 Cohort 5"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Sarcoma","id":"OG008","title":"Part 2 Cohort 6"}],"paramType":"MEDIAN","populationDescription":"PK population = All subjects in the full analysis set who underwent blood sampling for PK evaluation during the study.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 end of infusion; Cycle 3 Day 1 end of infusion (each cycle is 28 days, each infusion is up to 1 hour)","title":"To Evaluate the Concentration Level of AMG 655","type":"SECONDARY","unitOfMeasure":"μg/mL"}